Chronic Spontaneous Urticaria
Conditions
Brief summary
Mean change from baseline in UAS7 at Week 12
Detailed description
Mean change from baseline in ISS7 and HSS7 at Week 12, Percent of participants with UAS7 = 0 at Week 12, Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12, Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12., Percent of participants with UAS7 ≤ 6 at Week 12, Mean change from baseline in UAS7 at Week 4, Mean change from baseline in UAS7 at Week 24, Percent of participants with UAS7 = 0 at Week 24
Interventions
Sponsors
Celldex Therapeutics Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change from baseline in UAS7 at Week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean change from baseline in ISS7 and HSS7 at Week 12, Percent of participants with UAS7 = 0 at Week 12, Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12, Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12., Percent of participants with UAS7 ≤ 6 at Week 12, Mean change from baseline in UAS7 at Week 4, Mean change from baseline in UAS7 at Week 24, Percent of participants with UAS7 = 0 at Week 24 | — |
Countries
Belgium, Bulgaria, Czechia, Denmark, France, Germany, Greece, Italy, Poland, Portugal, Spain
Outcome results
None listed